MannKind Corporation (MNKD): Price and Financial Metrics
MNKD Price/Volume Stats
Current price | $4.53 | 52-week high | $5.75 |
Prev. close | $4.63 | 52-week low | $3.17 |
Day low | $4.49 | Volume | 2,578,139 |
Day high | $4.74 | Avg. volume | 3,205,179 |
50-day MA | $4.00 | Dividend yield | N/A |
200-day MA | $4.08 | Market Cap | 1.22B |
MNKD Stock Price Chart Interactive Chart >
MNKD POWR Grades
- MNKD scores best on the Growth dimension, with a Growth rank ahead of 96.47% of US stocks.
- MNKD's strongest trending metric is Value; it's been moving up over the last 26 weeks.
- MNKD's current lowest rank is in the Stability metric (where it is better than 17.43% of US stocks).
MNKD Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for MNKD is -0.7 -- better than just 5.88% of US stocks.
- Price to trailing twelve month operating cash flow for MNKD is currently 99.35, higher than 97.11% of US stocks with positive operating cash flow.
- Revenue growth over the past 12 months for MANNKIND CORP comes in at 131.61%, a number that bests 96.35% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to MANNKIND CORP are EVLV, DVAX, LNSR, EVBG, and EOSE.
- Visit MNKD's SEC page to see the company's official filings. To visit the company's web site, go to www.mannkindcorp.com.
MNKD Valuation Summary
- MNKD's price/sales ratio is 5.6; this is 33.33% higher than that of the median Healthcare stock.
- MNKD's price/sales ratio has moved NA NA over the prior 236 months.
Below are key valuation metrics over time for MNKD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
MNKD | 2023-12-29 | 5.6 | -3.9 | -31.4 | -206.7 |
MNKD | 2023-12-28 | 5.6 | -4.0 | -31.9 | -209.3 |
MNKD | 2023-12-27 | 5.6 | -3.9 | -31.5 | -207.5 |
MNKD | 2023-12-26 | 5.5 | -3.9 | -31.3 | -206.2 |
MNKD | 2023-12-22 | 5.5 | -3.9 | -31.0 | -204.9 |
MNKD | 2023-12-21 | 5.2 | -3.7 | -29.5 | -197.1 |
MNKD Growth Metrics
- Its 2 year net income to common stockholders growth rate is now at -102.86%.
- Its 3 year cash and equivalents growth rate is now at 91.81%.
- Its year over year price growth rate is now at -23.63%.
The table below shows MNKD's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 76.226 | -90.65 | -97.514 |
2022-06-30 | 65.612 | -77.761 | -87.508 |
2022-03-31 | 69.998 | -67.226 | -94.008 |
2021-12-31 | 75.442 | -61.709 | -80.926 |
2021-09-30 | 81.37 | -49.127 | -79.276 |
2021-06-30 | 74.511 | -47.403 | -86.105 |
MNKD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MNKD has a Quality Grade of C, ranking ahead of 42.97% of graded US stocks.
- MNKD's asset turnover comes in at 0.384 -- ranking 124th of 680 Pharmaceutical Products stocks.
- VERU, PLX, and LGND are the stocks whose asset turnover ratios are most correlated with MNKD.
The table below shows MNKD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.384 | 0.611 | -0.321 |
2021-03-31 | 0.424 | 0.627 | -0.330 |
2020-12-31 | 0.673 | 0.622 | -0.564 |
2020-09-30 | 0.673 | 0.595 | -0.391 |
2020-06-30 | 0.666 | 0.529 | -0.297 |
2020-03-31 | 0.705 | 0.516 | -0.324 |
MNKD Price Target
For more insight on analysts targets of MNKD, see our MNKD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $6.17 | Average Broker Recommendation | 1.33 (Strong Buy) |
MannKind Corporation (MNKD) Company Bio
MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. The company was founded in 1991 and is based in Valencia, California.
Latest MNKD News From Around the Web
Below are the latest news stories about MANNKIND CORP that investors may wish to consider to help them evaluate MNKD as an investment opportunity.
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco, Ca |
Insider Sell: CEO Michael Castagna Offloads 200,482 Shares of MannKind Corp (MNKD)In a significant move within the pharmaceutical industry, CEO Michael Castagna has parted with a substantial number of shares in MannKind Corp (NASDAQ:MNKD). |
High-Yield Haven: 3 Dividend Stocks to Secure NowThese are three different dividend stocks that have a great dividend yield and offer a reliable source of income. |
Investors in MannKind (NASDAQ:MNKD) have seen solid returns of 115% over the past five yearsIt hasn't been the best quarter for MannKind Corporation ( NASDAQ:MNKD ) shareholders, since the share price has fallen... |
MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call TranscriptMannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call Transcript November 7, 2023 MannKind Corporation beats earnings expectations. Reported EPS is $0.01, expectations were $-0.02. Operator: Good afternoon and welcome to the MannKind Corporation 2023 Third Quarter Financial Results Earnings Call. As a reminder, this call is being recorded on November 7th, 2023, and will be available […] |
MNKD Price Returns
1-mo | 19.84% |
3-mo | 24.45% |
6-mo | 9.69% |
1-year | 10.76% |
3-year | 24.45% |
5-year | 129.95% |
YTD | 24.45% |
2023 | -30.93% |
2022 | 20.59% |
2021 | 39.62% |
2020 | 142.64% |
2019 | 21.70% |
Continue Researching MNKD
Want to do more research on Mannkind Corp's stock and its price? Try the links below:Mannkind Corp (MNKD) Stock Price | Nasdaq
Mannkind Corp (MNKD) Stock Quote, History and News - Yahoo Finance
Mannkind Corp (MNKD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...